Proteolytic bacteria expansion during colitis amplifies inflammation through cleavage of the external domain of PAR2
Imbalances in proteolytic activity have been linked to the development of inflammatory bowel diseases (IBD) and experimental colitis. Proteases in the intestine play important roles in maintaining homeostasis, but exposure of mucosal tissues to excess proteolytic activity can promote pathology through protease-activated receptors (PARs). Previous research implicates microbial proteases in IBD, but the underlying pathways and specific interactions between microbes and PARs remain unclear. In this study, we investigated the role of microbial proteolytic activation of the external domain of PAR2 in intestinal injury using mice expressing PAR2 with a mutated N-terminal external domain that is resistant to canonical activation by proteolytic cleavage. Our findings demonstrate the key role of proteolytic cleavage of the PAR2 external domain in promoting intestinal permeability and inflammation during colitis. In wild-type mice expressing protease-sensitive PAR2, excessive inflammation leads to the expansion of bacterial taxa that cleave the external domain of PAR2, exacerbating colitis severity. In contrast, mice expressing mutated protease-resistant PAR2 exhibit attenuated colitis severity and do not experience the same proteolytic bacterial expansion. Colonization of wild-type mice with proteolytic PAR2-activating <i>Enterococcus</i> and <i>Staphylococcus</i> worsens colitis severity. Our study identifies a previously unknown interaction between proteolytic bacterial communities, which are shaped by inflammation, and the external domain of PAR2 in colitis. The findings should encourage new therapeutic developments for IBD by targeting excessive PAR2 cleavage by bacterial proteases.
Authors
- Corinne Rolland
- Jennifer A. Jury (ORCID: https://orcid.org/0000-0001-5444-3008)
- Giada De Palma (ORCID: https://orcid.org/0000-0002-2063-7741)
- Wolfram Ruf (ORCID: https://orcid.org/0000-0002-6064-2166)
- Heather J. Galipeau (ORCID: https://orcid.org/0000-0002-6413-0803)
- Přemysl Berčík (ORCID: https://orcid.org/0000-0001-8707-1781)
- L Rondeau (ORCID: https://orcid.org/0009-0000-7343-254X)
- Alba Santiago (ORCID: https://orcid.org/0000-0002-3773-8020)
- Miriam Bermúdez-Brito (ORCID: https://orcid.org/0000-0003-4156-143X)
- Amber Hann
- Nathalie Vergnolle (ORCID: https://orcid.org/0000-0003-1825-6015)
- Céline Deraison (ORCID: https://orcid.org/0000-0002-9013-4592)
- X Wang
- Alberto Caminero (ORCID: https://orcid.org/0000-0001-9555-7167)
- Elena F. Verdú (ORCID: https://orcid.org/0000-0001-6346-2665)
- B Barbosa da Luz
Institutions
- Scripps Research Institute (US)
- Université Toulouse III - Paul Sabatier (FR)
- Inserm (FR)
- École Nationale Vétérinaire de Toulouse (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Johannes Gutenberg University Mainz (DE)
- Population Health Research Institute (CA)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Institut de Recherche en Santé Digestive (FR)
- McMaster University (CA)
Publication Details
- Journal
- Gut Microbes
- Published
- 2024-08-22
- DOI
- https://doi.org/10.1080/19490976.2024.2387857
- Citations
- 17
- Primary Topic
- Blood Coagulation and Thrombosis Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 7.72
Funders
- AstraZeneca
- McMaster University
- Deutsche Forschungsgemeinschaft
- Agence Nationale de la Recherche
- Canadian Institutes of Health Research
- European Research Council
- CHIST-ERA